USCOM LIMITED — Regulatory Filings 2014

Feb 9, 2014

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

Uscom BP+ leading blood pressure technology; Global study

Monday 10th of February 2014: Uscom (ASX code: UCM)

Uscom Limited is pleased to note the release of a new global study of central Blood Pressure (cBP) which identifies cBP as a new clinical standard for hypertension, and Uscom BP+ as the leading device for measuring cBP when compared between 10 market competing devices. The independent study was authored by hypertension researchers from Cambridge University, Cambridge, UK, Wales Heart Institute, Cardiff, UK, Weill Cornell Medical College, New York, USA and the University of California, Irvine, USA.

The study reviewed current evidence supporting adoption of cBP over conventional BP measurement, and ranked cBP devices, awarding the Uscom BP+ a 4 star rating. The study concluded that cBP better predicts cardiovascular risk than conventional arm cuff blood pressure measurements, and that treatment based on cBP is likely to improve diagnosis and management of hypertension. In their assessment of the clinical applicability of current on-market devices, the BP+ technology was awarded 4 stars along with the Centron device. Other devices manufactured by Omron, Atcor, Skidmore, Tensiomed and HealthSTATS, all received 1 to 3 stars.

The current global BP device market is estimated at approximately $2b USD and growing at 11.5% per year. The Uscom BP+ is a break through BP technology based on patent protected suprasystolic oscillometry which is changing worldwide thinking on BP and hypertension treatment. The Uscom BP+ has FDA clearance and has completed the CE Mark process to sell into Europe.

Executive Chairman of Uscom, Rob Phillips said, “This review of the current science by the world’s leading hypertension experts comes at a great time for us as we negotiate global distribution and licensing agreements for BP+. The study confirms that cBP is the new gold standard measurement for hypertension, and that the Uscom BP+ is the gold standard cBP technology. As the rest of the world begins the upgrade from conventional BP to cBP technology, Uscom BP+ is a technology of choice, and we are now preparing to manufacture the device to meet this demand.”

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the way we diagnose and treat circulatory disease, including hypertension and heart failure, and for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies.

References:

• McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson AB. Central blood pressure: current evidence and clinical importance. Euro Heart J 2014;doi10.1093/eurojeartj/eht565 (The Uscom BP+ is referred to as the Pulsecor Cardioscope II in the study) http://eurheartj.oxfordjournals.org/content/early/2014/01/22/eurheartj.eht565.abstract - Avolio A. Central aortic blood pressure and management of hypertension: confirmation of a paradigm shift? Hypertension Editorial 2013; Sept 23

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

About Uscom

Uscom Limited is an ASX listed cardiovascular medical device company (UCM). Uscom is an innovative developer and manufacturer of premium cardiovascular devices and has two practice leading technologies in the field of cardiovascular monitoring, the USCOM 1A and the BP+. The devices are both clinically validated with FDA, CE and TGA regulatory approval, and are currently being marketed into global distribution networks.

The USCOM 1A is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anesthesia, and is the device of choice for management of adult and paediatric sepsis, and for the guidance of fluid therapy.

The Uscom BP+ is a supra systolic Central Blood Pressure monitor and replaces older and more widespread BP sub systolic Blood Pressure monitoring technology. Central Bood Pressure is becoming the new standard of care measurement in hypertension and heart failure. The Uscom BP+ provides a highly accurate & repeatable measurements of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in cardiology, intensive care, general practice and home care.

For more information, please visit: http://www.uscom.com.au.

Uscom Contacts Rob Phillips Executive Chairman rob@uscom.com.au

Catherine Officer Company Secretary secretary@uscom.com.au